Ever since dissolution was known to have a significant effect on bioavailability and clinical
performance, dissolution analysis of pharmaceutical solids has become one of the most …

Although there is a modest body of literature on the absorption of inhaled pharmaceuticals
by normal lungs and some limited information from diseased lungs, there is still a surprising …

Over the past 20 years, solution-based spray dried powders have transformed inhaled
product development, enabling aerosol delivery of a wider variety of molecules as dry …

In recent years there is an increasing interest in the pulmonary delivery of large cohesive
powder doses, ie drugs with a low potency such as antibiotics or drugs with a high potency …

Dry powder inhalers (DPIs) can be used with a wide range of drugs such as small molecules
and biologics and offer several advantages for inhaled therapy. Early DPI products were …

Pulmonary drug delivery is the promising delivery route to treat not only respiratory diseases
but also systemic diseases and has proven as a potential delivery route for complex drugs …

Dry Powder Inhalers play a major role in today's treatment of various respiratory diseases. A
lot of effort has been put into the optimization of a device and the appropriate formulation …

Delivering therapeutic agents to the airways maximizes their concentration in lung tissue,
decreasing systemic exposure or facilitating systemic absorption as desired. Many …

Medicines for delivering therapeutic agents to the lung as dry powders primarily consist of a
carrier and a micronised active pharmaceutical ingredient (API). The performance of an …

The use of physiologically based pharmacokinetic (PBPK) models to support drug product
development has become increasingly popular. The in vitro characterization of the materials …